* Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit ofKRW 312.8 billion....
* Samsung Biologics is one of 19 companies to have been awarded the 2022 Terra Carta Seal. * Th...
* Recorded consolidated revenue of KRW 873 billion in Q3'22 * Recorded consolidated operating pr...
* Receives accreditation for information security management system, information security in clou...
* Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned * Par...
* Two distinctive platforms will streamline the antibody development process. * With an advanced ...
* Rising from last year's ranking, the company's united effort and dedication to integrating sust...
* GreenLight's messenger RNA production process is transferable to large-scale equipment and CMO ...
* Released consolidated financial position of the company based on its full acquisition of Samsun...
* Acquires additional land, sized 357,366㎡ valued at KRW 426 billion, for Bio Campus 2 * Plans ...
* Aims to build an eco-friendly business environment and achieve net zero GHG emissions in its op...
* Q1'22 revenue of KRW 511.3 billion increased 96% compared to Q1'21. * Q1'22 operating profit o...
* Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary * Firs...
INCHEON, South Korea, March 28, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world'...
INCHEON, South Korea, Feb. 7, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's ...
* Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture ...
* Q4'21 revenue of KRW 444.3 billion increased 18% compared to Q4'20. * Q4'21 operating profit o...
INCHEON, South Korea, Jan. 12, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced it...
CAMBRIDGE, Mass. and INCHEON, South Korea, Dec. 14, 2021 /PRNewswire/ -- Moderna (Nasdaq: MRNA), a ...
INCHEON, South Korea, Dec. 13, 2021 /PRNewswire/ -- Samsung Biologics (207940.KS), the world's lead...
